Sun Pharmaceutical Industries Limited
6,467words
5turns
0analyst exchanges
0executives
Key numbers — 40 extracted
18%
14%
32%
Rs 433
rs
5
31%
19%
12%
16%
73.9%
73.1%
75.4%
Risks & concerns — 1 flagged
• In clinical trials, XELPROS demonstrated reductions from baseline in intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension8 • Current Markets: US All brand names and trademarks are the property of their respective owners © Sun Pharmaceutical Industries Limited.
— Source
Speaking time
3
1
1
Opening remarks
Note
(1) As of Jan, 03 2024 using spot exchange rate of INR /USD = 83.30 # Includes Western Europe, Canada, Japan, Australia & New Zealand, Israel and other markets. * Source: IQVIA data for 12 months ended Sept 2023 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 10 Driving sustainable long term growth • Achieve critical mass in key markets • Clear and actionable targets on sustainability • Embed sustainability practices in businesses i n v e s t m e n t s p r o f i t a b i l i t y & l B a a n c e Sustainable growth • Increase contribution of specialty and complex products • Direct future investments towards differentiated products • Optimize operational costs • Leverage benefits of vertically integrated operations t s o C i p h s r e d a e l Business development • Use acquisitions to bridge gaps while yielding target ROI • Focus on access to novel products, technology or market presence © Sun Pharmaceutical Industries Limited. All Rights Reserved. 11 ESG Performance - FY 202
Source
1, 2 & 4 Sun Press Release 3 Levulan website © Sun Pharmaceutical Industries Limited. All Rights Reserved. 15 Global Specialty portfolio Treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. • ODOMZO was shown to shrink laBCC in almost 6 out of 10 patients (56%) in a clinical study. laBCC Patients were treated with ODOMZO® and followed for at least 18 months5 • Currently marketed in US, Canada, Germany, France, Denmark, Switzerland, Spain, Italy, Australia and Israel To increase tear production in patients with keratoconjunctivitis sicca (dry eye) • Phase 3 confirmatory study observed clinically and statistically significant improvements in tear production and ocular surface integrity in patients6 • Current Markets: US, Canada • Out-licensed to CMS for Greater China in June 2019 Treatment of postoperative inflammation and prevention of ocula
Source
5 Product Label 6 Sun Press Release 7 & 8 Product website 16 Global Specialty portfolio In combination with methylprednisolone for the treatment of patients with metastatic castration resistant prostate cancer (CRPC). • YONSA® was shown in clinical studies to be an effective form of abiraterone acetate, and can be taken with or without food, in combination with methylprednisolone9 • Current Markets: US First and only product approved in the US for treating seizures in neonatal patients • NEOLEV2 study compared phenobarbital to levetiracetam in the first-line treatment of neonatal seizures. 24 hours following the administration, 73% vs. 25% were seizure-free in the respective groups10 • Current Markets: US For therapeutic solutions for long-term care (LTC) patients • Products using sprinkle technology for patients who have difficulty swallowing • Sprinkle versions of metoprolol (cardiology), rosuvastatin (cardiology) & duloxetine (neuro-psychiatry) • Current Markets: US All brand names
Source
9 & 10 Sun Press Release © Sun Pharmaceutical Industries Limited. All Rights Reserved. 17 Global Specialty pipeline Asset Indication Route of administration Mechanism of action Preclinical Phase 1 Phase 2 Phase 3 Registration CTP-543 (deuruxolitinib) alopecia areata Oral JAK Inhibitor Ilumya (tildrakizumab) psoriatic arthritis Injection IL-23 Antagonist Nidlegy™ skin cancer Injection Immunocytokines MM-II Pain in osteoarthritis Injection SCD-044 GL0034 psoriasis, atopic dermatitis Type 2 diabetes Oral Liposomal intra -articular lubrication Selective SIPR1 Agonist Injection GLP-1R Agonist All candidates for global markets except Nidlegy™ where Sun is commercial partner for Europe, Australia & New Zealand. Nidlegy™ is a trademark of Philogen. Creating Lasting Value - Investor Presentation 18 US Formulations 31% of FY23 Revenues © Sun Pharmaceutical Industries Limited. All Rights Reserved. 19 US highlights Significant Specialty presence/12th largest in US Generics* Dermatology segment Ran
Net Profit Adjustment
#H1FY24 - Adjusted for Rs 3.2 Bn related to (i) Impairment of intangible under development of Ache Labs = Rs. 1,492 mn (ii) Nigeria Forex loss =Rs. 1,229 mn (iii) Alchemee restructuring cost =Rs. 507 mn. © Sun Pharmaceutical Industries Limited. All Rights Reserved. 51 Sales split Q2 FY24 Q2 FY24 Q2 FY23 CHANGE H1 FY24 ( All Figures in Rs mn ) CHANGE H1 FY23 Formulation India US Emerging Markets ROW # ÀPI Others 38,425 35,504 23,449 17,000 34,600 32,913 20,704 14,441 Sub-total 114,379 102,658 4,972 680 4,730 704 11.1% 7.9% 13.3% 17.7% 11.4% 5.1% -3.4% 74,029 74,213 44,901 33,041 68,471 65,350 39,615 29,119 226,184 202,555 10,368 1,331 10,717 1,260 8.1% 13.6% 13.3% 13.5% 11.7% -3.3% 5.7% Gross Sales 120,031 108,092 11.0% 237,883 214,532 10.9% US Formulations India Branded Generics Emerging Markets Rest of World API & Others 32% 19% 32% 19% Q2 FY24 30% 14% 5% Q2 FY23 31% 13% 5% # ROW includes Western Europe, Canada, Japan, Australia, New Zealand, Israel and other markets © Sun Pharmaceuti